Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis

BACKGROUND: Mavoglurant (AFQ056), a selective metabotropic glutamate receptor 5 (mGluR5) inhibitor, was tested for t levodopa-induced dyskinesia (LID) in patients with Parkinson’s Disease (PD). However, clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID...

Descripción completa

Detalles Bibliográficos
Autores principales: Negida, Ahmed, Ghaith, Hazem S., Fala, Salma Yousry, Ahmed, Hussien, Bahbah, Eshak I, Ebada, Mahmoud Ahmed, Aziz, Mohamed Abd Elalem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342336/
https://www.ncbi.nlm.nih.gov/pubmed/34014397
http://dx.doi.org/10.1007/s10072-021-05319-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342336/
https://www.ncbi.nlm.nih.gov/pubmed/34014397
http://dx.doi.org/10.1007/s10072-021-05319-7

Ejemplares similares